GlassScriptPhysician profile
Tanya Elmas
NPI 1790360543
$1,744.08
in general payments reported to CMS, 2019-2025
22 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.58 · 2022: $220 · 2023: $613 · 2024: $490 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $470.45 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $237.62 | 2022-2025 | |
| Lilly USA, LLC | $174.20 | 2023-2025 | Mounjaro |
| Dexcom, INC. | $157.23 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.54 | 2021-2023 | |
| Lundbeck LLC | $74.35 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $70.20 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $53.54 | 2025 | Breztri |
| Boston Scientific Corporation | $44.12 | 2022 | |
| Amgen INC. | $43.33 | 2022-2024 | Krystexxa, Prolia, Evenity |
| Astellas Pharma US INC | $37.38 | 2021 | |
| Corcept Therapeutics | $36.14 | 2025 | Korlym |
| Ardelyx, INC. | $34.19 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $33.74 | 2024 | Trelegy Ellipta |
| Almatica Pharma LLC | $27.60 | 2024 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.04 | 2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $21.48 | 2023 | Krystexxa |
| Novo Nordisk INC | $20.08 | 2023 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $19.10 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $18.69 | 2023 | Xarelto |
| Pfizer INC. | $16.90 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Elmas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.